Cargando…
Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate difference...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357407/ https://www.ncbi.nlm.nih.gov/pubmed/37485441 http://dx.doi.org/10.2144/fsoa-2023-0049 |
_version_ | 1785075487280726016 |
---|---|
author | Dionese, Michele Basso, Umberto Pierantoni, Francesco Lai, Eleonora Cavasin, Nicolò Erbetta, Elisa Jubran, Salim Bonomi, Giorgio Bimbatti, Davide Maruzzo, Marco |
author_facet | Dionese, Michele Basso, Umberto Pierantoni, Francesco Lai, Eleonora Cavasin, Nicolò Erbetta, Elisa Jubran, Salim Bonomi, Giorgio Bimbatti, Davide Maruzzo, Marco |
author_sort | Dionese, Michele |
collection | PubMed |
description | AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences in OS, response rate and toxicities, according to baseline inflammation indexes values. RESULTS: neutrophil-to-lymphocite ratio (NLR) <3 was associated to longer progression-free survival (PFS; 4.9 vs 3.1 months) and OS (15.7 vs 7.6 months); monocyte-to-lymphocite ratio (MLR) <0.4 was associated to longer PFS (4.6 vs 2.8 months). Overall response rate (ORR), disease control rate (DCR) were higher in these patients. Patients with an irAE had longer PFS and OS. CONCLUSION: baseline inflammatory indexes are prognostic for mUC patients treated with ICIs. |
format | Online Article Text |
id | pubmed-10357407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Future Science Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-103574072023-07-21 Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy Dionese, Michele Basso, Umberto Pierantoni, Francesco Lai, Eleonora Cavasin, Nicolò Erbetta, Elisa Jubran, Salim Bonomi, Giorgio Bimbatti, Davide Maruzzo, Marco Future Sci OA Research Article AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences in OS, response rate and toxicities, according to baseline inflammation indexes values. RESULTS: neutrophil-to-lymphocite ratio (NLR) <3 was associated to longer progression-free survival (PFS; 4.9 vs 3.1 months) and OS (15.7 vs 7.6 months); monocyte-to-lymphocite ratio (MLR) <0.4 was associated to longer PFS (4.6 vs 2.8 months). Overall response rate (ORR), disease control rate (DCR) were higher in these patients. Patients with an irAE had longer PFS and OS. CONCLUSION: baseline inflammatory indexes are prognostic for mUC patients treated with ICIs. Future Science Ltd 2023-06-24 /pmc/articles/PMC10357407/ /pubmed/37485441 http://dx.doi.org/10.2144/fsoa-2023-0049 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Research Article Dionese, Michele Basso, Umberto Pierantoni, Francesco Lai, Eleonora Cavasin, Nicolò Erbetta, Elisa Jubran, Salim Bonomi, Giorgio Bimbatti, Davide Maruzzo, Marco Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy |
title | Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy |
title_full | Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy |
title_fullStr | Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy |
title_full_unstemmed | Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy |
title_short | Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy |
title_sort | prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357407/ https://www.ncbi.nlm.nih.gov/pubmed/37485441 http://dx.doi.org/10.2144/fsoa-2023-0049 |
work_keys_str_mv | AT dionesemichele prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT bassoumberto prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT pierantonifrancesco prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT laieleonora prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT cavasinnicolo prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT erbettaelisa prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT jubransalim prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT bonomigiorgio prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT bimbattidavide prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy AT maruzzomarco prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy |